Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 400 articles:
HTML format



Single Articles


    December 2022
  1. VUIJK SA, de Ridder L
    Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56.
    PubMed    


  2. KULYK A, Shafer LA, Graff LA, Stone J, et al
    Urgency for bowel movements is a highly discriminatory symptom of active disease in persons with IBD (the Manitoba Living with IBD study).
    Aliment Pharmacol Ther. 2022;56.
    PubMed     Abstract available


    November 2022
  3. BUISSON A, Nachury M, Guilmoteau T, Altwegg R, et al
    Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
    Aliment Pharmacol Ther. 2022 Nov 19. doi: 10.1111/apt.17305.
    PubMed     Abstract available


  4. CORTESI PA, Fiorino G, Peyrin-Biroulet L, Mantovani LG, et al
    Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Nov 15. doi: 10.1111/apt.17261.
    PubMed     Abstract available


  5. ZISMAN-ILANI Y, Thompson KD, Siegel LS, Mackenzie T, et al
    Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial.
    Aliment Pharmacol Ther. 2022 Nov 14. doi: 10.1111/apt.17286.
    PubMed     Abstract available


  6. YUAN S, Sun Y, Tan X, Geng J, et al
    Sleep duration and daytime napping in relation to incident inflammatory bowel disease: a prospective cohort study.
    Aliment Pharmacol Ther. 2022 Nov 9. doi: 10.1111/apt.17285.
    PubMed     Abstract available


  7. EVERHOV AH, Olen O
    Editorial: colorectal cancer in elderly-onset IBD-what is the risk? Authors' reply.
    Aliment Pharmacol Ther. 2022;56:1423-1424.
    PubMed    


  8. WEISS A, Buchner AM
    Editorial: colorectal cancer in elderly-onset inflammatory bowel disease-what is the risk?
    Aliment Pharmacol Ther. 2022;56:1421-1422.
    PubMed    


  9. LEE KE, Faye AS
    Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:1427-1428.
    PubMed    


  10. SAHYOUN L, Dahiya DS, Cheng CI, Sultan K, et al
    Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism.
    Aliment Pharmacol Ther. 2022;56:1425-1426.
    PubMed    


  11. BEZZIO C, Alimenti E, Saibeni S
    Letter: immune-mediated inflammatory diseases and inflammatory bowel disease-are we ready for a Copernican revolution?
    Aliment Pharmacol Ther. 2022;56:1429-1430.
    PubMed    


  12. DAHL EK, Abed OK, Kjeldsen J, Donia M, et al
    Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis.
    Aliment Pharmacol Ther. 2022;56:1370-1382.
    PubMed     Abstract available


  13. NORGARD BM, Friedman S, Kjeldsen J, Nielsen J, et al
    The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study.
    Aliment Pharmacol Ther. 2022;56:1349-1360.
    PubMed     Abstract available


  14. RONNOW SAND J, Troelsen FS, Horvath-Puho E, Henderson VW, et al
    Letter: comedication use and dementia risk in patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1505-1506.
    PubMed    


  15. CHANG HC, Gau SY
    Letter: comedication use and dementia risk in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1503-1504.
    PubMed    


  16. REIJNTJES MA, de Voogd FAE, Bemelman WA, Hompes R, et al
    Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls - a prospective cohort study.
    Aliment Pharmacol Ther. 2022 Nov 1. doi: 10.1111/apt.17267.
    PubMed     Abstract available


    October 2022
  17. COLMAN RJ, Mizuno T, Fukushima K, Haslam DB, et al
    Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance.
    Aliment Pharmacol Ther. 2022 Oct 31. doi: 10.1111/apt.17277.
    PubMed     Abstract available


  18. STRAATMIJER T, van Schaik FDM, Bodelier AGL, Visschedijk M, et al
    Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry.
    Aliment Pharmacol Ther. 2022 Oct 25. doi: 10.1111/apt.17248.
    PubMed     Abstract available


  19. SAIFUDDIN A, Kent AJ, Mehta SJ, Hicks LC, et al
    Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Oct 5. doi: 10.1111/apt.17223.
    PubMed     Abstract available


  20. BURGESS CJ, Jackson R, Chalmers I, Russell RK, et al
    The inexorable increase of biological exposure in paediatric inflammatory bowel disease: a Scottish, population-based, longitudinal study.
    Aliment Pharmacol Ther. 2022 Oct 4. doi: 10.1111/apt.17217.
    PubMed     Abstract available


  21. BURISCH J
    Editorial: trends in the epidemiology of inflammatory bowel disease in Korea.
    Aliment Pharmacol Ther. 2022;56:1207-1208.
    PubMed    


  22. BODGER K
    Editorial: rising rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease in the USA.
    Aliment Pharmacol Ther. 2022;56:1211-1212.
    PubMed    


  23. SHIM JO
    Editorial: trends in the epidemiology of inflammatory bowel disease in Korea - author's reply.
    Aliment Pharmacol Ther. 2022;56:1209-1210.
    PubMed    


  24. LEE KE, Faye AS
    Editorial: rising rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease in the USA-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1213-1214.
    PubMed    


  25. CHOI SY, Kim ES, Jeon TY, Lee YM, et al
    Transmural healing evaluated by magnetic resonance enterography in paediatric patients with Crohn's disease receiving maintenance treatment with biologics.
    Aliment Pharmacol Ther. 2022;56:1146-1156.
    PubMed     Abstract available


  26. SHIN A
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1300-1301.
    PubMed    


  27. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Editorial: natural history of irritable bowel syndrome in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1302-1303.
    PubMed    


    September 2022
  28. AVNI-BIRON I, Mishael T, Zittan E, Livne-Margolin M, et al
    Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Sep 27. doi: 10.1111/apt.17224.
    PubMed     Abstract available


  29. BLACK J, Sweeney L, Yuan Y, Singh H, et al
    Systematic review: the role of psychological stress in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Sep 8. doi: 10.1111/apt.17202.
    PubMed     Abstract available


  30. ROSIOU K, Selinger CP
    Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:898-899.
    PubMed    


  31. HAYDEK JP, Scott FI
    Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with IBD.
    Aliment Pharmacol Ther. 2022;56:896-897.
    PubMed    


  32. BERTANI L, Trico D
    Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue.
    Aliment Pharmacol Ther. 2022;56:903-904.
    PubMed    


  33. HUDSON AS, Wine E
    Editorial: further support for exclusive enteral nutrition in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:900-901.
    PubMed    


  34. KANE S
    Editorial: paternal use of IBD therapies and risk of infant infection.
    Aliment Pharmacol Ther. 2022;56:902.
    PubMed    


  35. LIN S, Chanchlani N, Carbery I, Janjua M, et al
    Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naive patients with active luminal Crohn's disease?
    Aliment Pharmacol Ther. 2022;56:783-793.
    PubMed     Abstract available


  36. ATIA O, Pujol-Muncunill G, Navas-Lopez VM, Orlanski-Meyer E, et al
    Children included in randomised controlled trials of biologics in inflammatory bowel diseases do not represent the real-world patient mix.
    Aliment Pharmacol Ther. 2022;56:794-801.
    PubMed     Abstract available


  37. LIMA CCG, Peerani F
    Editorial: IBD and the risk of dementia - the jury is still out.
    Aliment Pharmacol Ther. 2022;56:1078-1079.
    PubMed    


  38. LOPES EW, Khalili H
    Editorial: investigating the association between sweetened beverages and risk of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:1086-1087.
    PubMed    


  39. FU T, Wang X, Chen J
    Editorial: investigating the association between sweetened beverages and risk of inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1088-1089.
    PubMed    


  40. HENDERSON P
    Editorial: earning potential in paediatric-onset IBD-a complex interplay.
    Aliment Pharmacol Ther. 2022;56:1084-1085.
    PubMed    


  41. ZHAO M, Lirhus S, Lordal M, Langholz E, et al
    Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
    Aliment Pharmacol Ther. 2022;56:989-1006.
    PubMed     Abstract available


  42. VOLKERS A, Straatmijer T, Duijvestein M, Sales A, et al
    Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2022;56:1044-1054.
    PubMed     Abstract available


    August 2022
  43. CHANCHLANI N, Lin S, Auth MK, Lee CL, et al
    Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
    Aliment Pharmacol Ther. 2022 Aug 29. doi: 10.1111/apt.17170.
    PubMed     Abstract available


  44. FAIRBRASS KM, Hamlin PJ, Gracie DJ, Ford AC, et al
    Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up.
    Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17193.
    PubMed     Abstract available


  45. IRVING PM, Leung Y, Dubinsky MC
    Review article: guide to tofacitinib dosing in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Aug 22. doi: 10.1111/apt.17185.
    PubMed     Abstract available


  46. MALMBORG P, Everhov AH, Soderling J, Ludvigsson JF, et al
    Earnings during adulthood in patients with childhood-onset inflammatory bowel disease: A nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2022 Aug 2. doi: 10.1111/apt.17148.
    PubMed     Abstract available


  47. EVERHOV AH, Erichsen R, Jaras J, Pedersen L, et al
    Colorectal cancer in elderly-onset inflammatory bowel disease: A 1969-2017 Scandinavian register-based cohort study.
    Aliment Pharmacol Ther. 2022 Aug 2. doi: 10.1111/apt.17175.
    PubMed     Abstract available


  48. SOHOULI MH, Fatahi S, Farahmand F, Alimadadi H, et al
    Meta-analysis: efficacy of exclusive enteral nutrition as induction therapy on disease activity index, inflammation and growth factors in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:384-395.
    PubMed     Abstract available


  49. TAXONERA C
    Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis-Author's reply.
    Aliment Pharmacol Ther. 2022;56:737-738.
    PubMed    


  50. HAWTHORNE AB, Lamb CA
    Editorial: quality assessment in IBD in high resource countries can lead to quality improvement clues for IBD management worldwide-authors' reply.
    Aliment Pharmacol Ther. 2022;56:743.
    PubMed    


  51. MANTZARIS GJ, Papamichael K
    Editorial: golimumab thresholds to achieve stringent medium- and long-term therapeutic outcomes in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022;56:735-736.
    PubMed    


  52. PUGLIESE D, Privitera G, Armuzzi A
    Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:733-734.
    PubMed    


  53. BERNSTEIN CN
    Editorial: quality assessment in IBD in high-resource countries can lead to quality improvement clues for IBD management worldwide.
    Aliment Pharmacol Ther. 2022;56:741-742.
    PubMed    


  54. KEEFER L, Shapiro MJ
    Editorial: measuring disease severity in inflammatory bowel disease-the whole is greater than the sum of its parts.
    Aliment Pharmacol Ther. 2022;56:744-745.
    PubMed    


  55. LEE H, Khan N
    Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease - the IG-IBD LIVE study.
    Aliment Pharmacol Ther. 2022;56:731-732.
    PubMed    


  56. GOLD SL, Raman M
    Editorial: a formula shake each day keeps the complications away - the tolerability and effect of orally-delivered enteral nutrition in improving post-operative outcomes in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:739-740.
    PubMed    


  57. SWAMINATHAN A, Mules TC, Gearry RB
    Editorial: measuring disease severity in inflammatory bowel disease-the whole is greater than the sum of its parts. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:746-747.
    PubMed    


  58. MEADE S, Patel KV, Luber RP, O'Hanlon D, et al
    A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre.
    Aliment Pharmacol Ther. 2022;56:646-663.
    PubMed     Abstract available


  59. BOURGONJE AR, Alexdottir MS, Otten AT, Loveikyte R, et al
    Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:675-693.
    PubMed     Abstract available


    July 2022
  60. FAYE AS, Lee KE, Dodson J, Chodosh J, et al
    Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis.
    Aliment Pharmacol Ther. 2022 Jul 25. doi: 10.1111/apt.17162.
    PubMed     Abstract available


  61. FU T, Chen H, Chen X, Sun Y, et al
    Sugar-sweetened beverages, artificially sweetened beverages and natural juices and risk of inflammatory bowel disease: a cohort study of 121,490 participants.
    Aliment Pharmacol Ther. 2022 Jul 18. doi: 10.1111/apt.17149.
    PubMed     Abstract available


  62. REZAZADEH ARDABILI A, Jeuring S, Mujagic Z, Oostenbrug L, et al
    Classic drugs in the time of new drugs: Real-world, long-term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17128.
    PubMed     Abstract available


  63. CHOE YJ, Han K, Shim JO
    Treatment patterns of anti-tumour necrosis factor-alpha and prognosis of paediatric and adult-onset inflammatory bowel disease in Korea: a nationwide population-based study.
    Aliment Pharmacol Ther. 2022 Jul 6. doi: 10.1111/apt.17125.
    PubMed     Abstract available


  64. BIRON A, Beaugerie L, Chazouilleres O, Kirchgesner J, et al
    Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Jul 4. doi: 10.1111/apt.17123.
    PubMed     Abstract available


  65. SAND JR, Troelsen FS, Horvath-Puho E, Henderson VW, et al
    Risk of dementia in patients with inflammatory bowel disease: a Danish population-based study.
    Aliment Pharmacol Ther. 2022 Jul 3. doi: 10.1111/apt.17119.
    PubMed     Abstract available


  66. QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
    Letter: normalizing the ileoanal pouch-more than a one-step technique. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:176-177.
    PubMed    


  67. WEST J, Card TR, Crooks CJ
    Editorial: seeing the light at the end of gastroscope - complications after elective procedures are ready for NICE, bright decision aid tools - authors' reply.
    Aliment Pharmacol Ther. 2022;56:157.
    PubMed    


  68. HADI Y, Kochhar GS
    Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic-authors' reply.
    Aliment Pharmacol Ther. 2022;56:178.
    PubMed    


  69. LO SW, Garg M, Segal JP
    Letter: normalising the ileoanal pouch-more than a one-step technique.
    Aliment Pharmacol Ther. 2022;56:174-175.
    PubMed    


  70. BHURWAL A, Mutneja H, Seril D
    Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:164-165.
    PubMed    


  71. BENCHIMOL EI, Kuenzig ME
    Editorial: COVID-19 vaccines are safe and effective in patients with inflammatory bowel disease-but many unanswered questions remain.
    Aliment Pharmacol Ther. 2022;56:162-163.
    PubMed    


  72. HADI Y, Kochhar GS
    Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:179.
    PubMed    


  73. FEHILY SR, Al-Ani AH, Abdelmalak J, Rentch C, et al
    Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.
    Aliment Pharmacol Ther. 2022;56:6-27.
    PubMed     Abstract available


  74. VAUGHAN R, Tjandra D, Patwardhan A, Mingos N, et al
    Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:84-94.
    PubMed     Abstract available


  75. LYONS M, Derikx LAAP, Fulforth J, McCall S, et al
    Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis.
    Aliment Pharmacol Ther. 2022;56:67-76.
    PubMed     Abstract available


  76. ROBLIN X, Veyrard P, Bastide L, Berger AE, et al
    Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease.
    Aliment Pharmacol Ther. 2022;56:77-83.
    PubMed     Abstract available


  77. MASSIRONI S, Vigano C, Danese S
    Letter: pancreatic involvement in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;56:371.
    PubMed    


  78. DAI C, Huang YH
    Letter: pancreatic involvement in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:370.
    PubMed    


  79. SOLITANO V, Armuzzi A
    Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis-a step towards precision medicine?
    Aliment Pharmacol Ther. 2022;56:347-348.
    PubMed    


  80. FRIEDMAN S
    Editorial: measuring fertility in men with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;56:345-346.
    PubMed    


  81. GILL M, Majumdar A
    Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game.
    Aliment Pharmacol Ther. 2022;56:353-354.
    PubMed    


  82. KO KL, Hung IF, Leung WK
    Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease-time to get some skin in the game. Authors' reply.
    Aliment Pharmacol Ther. 2022;56:355-356.
    PubMed    


  83. MADSEN GR, Wilkens R, Boysen T, Burisch J, et al
    The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases-an international Delphi consensus survey.
    Aliment Pharmacol Ther. 2022;56:263-270.
    PubMed     Abstract available


  84. PUGLIESE D, Privitera G, Crispino F, Mezzina N, et al
    Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
    Aliment Pharmacol Ther. 2022;56:95-109.
    PubMed     Abstract available


    June 2022
  85. UMAR N, King D, Chandan JS, Bhala N, et al
    The association between inflammatory bowel disease and mental ill health: A retrospective cohort study using data from UK primary care.
    Aliment Pharmacol Ther. 2022 Jun 30. doi: 10.1111/apt.17110.
    PubMed     Abstract available


  86. FRIEDMAN S, Garvik OS, Nielsen J, Norgard BM, et al
    Paternal use of medications for inflammatory bowel disease and the risk of hospital-diagnosed infections in the offspring: A nationwide cohort study.
    Aliment Pharmacol Ther. 2022 Jun 30. doi: 10.1111/apt.17113.
    PubMed     Abstract available


  87. YUAN WQ, Li F, Yang LC, Yang ZL, et al
    Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic.
    Aliment Pharmacol Ther. 2022;55:1464-1465.
    PubMed    


  88. WANG CY, Lai CC
    Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1462-1463.
    PubMed    


  89. QUINN KP, Busciglio IA, Burton DD, Inoue A, et al
    Defining normal pouch function in patients with ileal pouch-anal anastomosis: a pilot study.
    Aliment Pharmacol Ther. 2022;55:1560-1568.
    PubMed     Abstract available


  90. HAWTHORNE AB, Glatter J, Blackwell J, Ainley R, et al
    Inflammatory bowel disease patient-reported quality assessment should drive service improvement: A national survey of UK IBD units and patients.
    Aliment Pharmacol Ther. 2022 Jun 1. doi: 10.1111/apt.17042.
    PubMed     Abstract available


    May 2022
  91. SWAMINATHAN A, Fan D, Borichevsky GM, Mules TC, et al
    The disease severity index for inflammatory bowel disease is associated with psychological symptoms, quality of life and predicts a more complicated disease course.
    Aliment Pharmacol Ther. 2022 May 27. doi: 10.1111/apt.17058.
    PubMed     Abstract available


  92. ROSIOU K, Carbonell J, Dolby V, Monfared N, et al
    Sources of excess steroid prescriptions and clinical adverse outcomes associated with steroid excess in patients with inflammatory bowel disease: The Leeds IBD Steroids study.
    Aliment Pharmacol Ther. 2022 May 24. doi: 10.1111/apt.17039.
    PubMed     Abstract available


  93. DRUVEFORS E, Andersson RE, Hammar U, Landerholm K, et al
    Minor impact on fertility in men with inflammatory bowel disease: A National Cohort Study from Sweden.
    Aliment Pharmacol Ther. 2022 May 22. doi: 10.1111/apt.16984.
    PubMed     Abstract available


  94. KO KL, Lam YF, Cheung KS, Hung IF, et al
    Clinical trial: intra-dermal hepatitis B vaccination with topical imiquimod versus intra-muscular hepatitis B vaccination in inflammatory bowel disease patients.
    Aliment Pharmacol Ther. 2022 May 11. doi: 10.1111/apt.16970.
    PubMed     Abstract available


  95. TAXONERA C, Fernandez-Acenero MJ, Olivares D, Calvo M, et al
    Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 May 4. doi: 10.1111/apt.16964.
    PubMed     Abstract available


  96. MASSIRONI S, Fanetti I, Vigano C, Pirola L, et al
    Systematic review-Pancreatic involvement in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 May 3. doi: 10.1111/apt.16949.
    PubMed     Abstract available


  97. FALLOON K, Cohen B, Rieder F
    Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1208-1209.
    PubMed    


  98. HADI Y, Kochhar GS
    Letter: association between COVID-19 and inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1228-1229.
    PubMed    


  99. KOKKOTIS G, Kitsou K, Bamias G
    Letter: COVID-19 outcomes and anti-TNF treatments-comprehensive evidence matters. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1235-1236.
    PubMed    


  100. ARDALAN ZS, Friedman AB
    Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment.
    Aliment Pharmacol Ther. 2022;55:1202-1203.
    PubMed    


  101. GUILLO L, Peyrin-Biroulet L, Danese S
    Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1206-1207.
    PubMed    


  102. BURISCH J, Langholz E, Munkholm P
    Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1239-1240.
    PubMed    


  103. CHEN HY, Wang SI, Chang R, Wei JC, et al
    Letter: association between COVID-19 and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1226-1227.
    PubMed    


  104. DEMARZO MG, Viola A, Picci A, Fries W, et al
    Letter: the clinical course of Crohn's disease-the Sicilian experience.
    Aliment Pharmacol Ther. 2022;55:1237-1238.
    PubMed    


  105. SAGAMI S, Kobayashi T
    Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1204-1205.
    PubMed    


  106. BACHOUR SP, Shah RS, Lyu R, Rieder F, et al
    Mild neoterminal ileal post-operative recurrence of Crohn's disease conveys higher risk for severe endoscopic disease progression than isolated anastomotic lesions.
    Aliment Pharmacol Ther. 2022;55:1139-1150.
    PubMed     Abstract available


  107. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:1151-1159.
    PubMed     Abstract available


  108. WANG J, Goren I, Rieder F
    Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1360.
    PubMed    


  109. FERNANDES RG, Radford-Smith G
    Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?
    Aliment Pharmacol Ther. 2022;55:1350-1351.
    PubMed    


  110. RADEKE HH, Stein J
    Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1359.
    PubMed    


  111. OKABAYASHI S, Yamazaki H, Matsuoka K, Yamamoto Y, et al
    Editorial: is older-onset ulcerative colitis more severe or less aggressively managed? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:1352-1353.
    PubMed    


  112. KUMAR P, Vuyyuru SK, Kedia S, Ahuja V, et al
    Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF-therapy-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1348-1349.
    PubMed    


  113. LOVATT J, Selinger CP
    Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti-TNF therapy.
    Aliment Pharmacol Ther. 2022;55:1346-1347.
    PubMed    


    April 2022
  114. VERSTOCKT B, Volk V, Jaeckel C, Alsoud D, et al
    Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Apr 28. doi: 10.1111/apt.16955.
    PubMed     Abstract available


  115. VANDE CASTEELE N, Sandborn WJ, Feagan BG, Vermeire S, et al
    Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study.
    Aliment Pharmacol Ther. 2022 Apr 27. doi: 10.1111/apt.16937.
    PubMed     Abstract available


  116. BERGQVIST V, Holmgren J, Klintman D, Marsal J, et al
    Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Apr 25. doi: 10.1111/apt.16927.
    PubMed     Abstract available


  117. HALFVARSON JF, Ludvigsson JF, Bresso F, Askling J, et al
    Age determines the risk of familial inflammatory bowel disease-A nationwide study.
    Aliment Pharmacol Ther. 2022 Apr 22. doi: 10.1111/apt.16938.
    PubMed     Abstract available


  118. MOENS A, Sadat Seyed Tabib N, Ballet V, Sabino J, et al
    Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral Centre.
    Aliment Pharmacol Ther. 2022 Apr 20. doi: 10.1111/apt.16928.
    PubMed     Abstract available


  119. KHALILI H, Casey K
    Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs-authors' reply.
    Aliment Pharmacol Ther. 2022;55:884.
    PubMed    


  120. YIN JQ, Wang BQ, Chen ZB, He HD, et al
    Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs.
    Aliment Pharmacol Ther. 2022;55:882-883.
    PubMed    


  121. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Letter: inflammatory bowel disease services during the Covid-19 pandemic.
    Aliment Pharmacol Ther. 2022;55:1063.
    PubMed    


  122. DEPUTY M, Hart A, Faiz O
    Letter: inflammatory bowel disease services during the Covid-19 pandemic - authors' reply.
    Aliment Pharmacol Ther. 2022;55:1064.
    PubMed    


  123. SELINGER CP, Lenti MV, De Silvestri A
    Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:1070-1071.
    PubMed    


  124. ADOMI M, Ray A
    Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:1069.
    PubMed    


  125. KIM ES, Choi S, Choi SY, Park JH, et al
    NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
    Aliment Pharmacol Ther. 2022;55:1008-1015.
    PubMed     Abstract available


  126. ALSOUD D, Verstockt B, Vermeire S
    Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era.
    Aliment Pharmacol Ther. 2022;55:885-886.
    PubMed    


  127. YANG H, Li B, Guo Q, Tang J, et al
    Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2022;55:764-777.
    PubMed     Abstract available


  128. LENTI MV, Dolby V, Clark T, Hall V, et al
    A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
    Aliment Pharmacol Ther. 2022;55:856-866.
    PubMed     Abstract available


    March 2022
  129. BHURWAL A, Mutneja H, Bansal V, Goel A, et al
    Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: A systematic review, meta-analysis and meta-regression.
    Aliment Pharmacol Ther. 2022 Mar 30. doi: 10.1111/apt.16913.
    PubMed     Abstract available


  130. TOWNSEND CM, Lovegrove F, Khanna R, Wilson AS, et al
    Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 21. doi: 10.1111/apt.16883.
    PubMed     Abstract available


  131. ZAMANI M, Alizadeh-Tabari S, Singh S, Loomba R, et al
    Meta-analysis: Prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16879.
    PubMed     Abstract available


  132. OKABAYASHI S, Yamazaki H, Tominaga K, Miura M, et al
    Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: A multicentre cohort study.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16865.
    PubMed     Abstract available


  133. FALLOON K, Cohen B, Ananthakrishnan AN, Barnes EL, et al
    A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 11. doi: 10.1111/apt.16853.
    PubMed     Abstract available


  134. SINGH AK, Jena A, Mahajan G, Mohindra R, et al
    Meta-analysis: Hepatitis B vaccination in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16880.
    PubMed     Abstract available


  135. SUNG KY, Zhang B, Wang HE, Bai YM, et al
    Schizophrenia and risk of new-onset inflammatory bowel disease: a nationwide longitudinal study.
    Aliment Pharmacol Ther. 2022 Mar 8. doi: 10.1111/apt.16856.
    PubMed     Abstract available


  136. PANACCIONE R, Abreu MT, Lazariciu I, Mundayat R, et al
    Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open.
    Aliment Pharmacol Ther. 2022 Mar 5. doi: 10.1111/apt.16848.
    PubMed    


  137. JAYASOORIYA N, Blackwell J, Saxena S, Bottle A, et al
    Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population-based study.
    Aliment Pharmacol Ther. 2022 Mar 4. doi: 10.1111/apt.16820.
    PubMed     Abstract available


  138. SAVELKOUL EHJ, Hoentjen F
    Editorial: anti-TNF combination therapy for inflammatory bowel disease-one size does not fit all.
    Aliment Pharmacol Ther. 2022;55:750-751.
    PubMed    


  139. HONAP S, Dart RJ, Samaan MA
    Editorial: protecting hypoxia-inducible factor-1alpha and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis?
    Aliment Pharmacol Ther. 2022;55:733-734.
    PubMed    


  140. DANESE S, Levesque BG, Feagan BG, Jucov A, et al
    Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:735-736.
    PubMed    


  141. KUMAR P, Vuyyuru SK, Kante B, Sahu P, et al
    Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
    Aliment Pharmacol Ther. 2022 Mar 1. doi: 10.1111/apt.16839.
    PubMed     Abstract available


  142. ZHAO M, Sall Jensen M, Knudsen T, Kelsen J, et al
    Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases - a Danish nationwide cohort study.
    Aliment Pharmacol Ther. 2022;55:541-557.
    PubMed     Abstract available


  143. COLMAN RJ, Xiong Y, Mizuno T, Hyams JS, et al
    Antibodies-to-infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:593-603.
    PubMed     Abstract available


  144. COHEN NA, Pekow J
    Editorial: time to modify practice and use the modified Rutgeert's score.
    Aliment Pharmacol Ther. 2022;55:754-755.
    PubMed    


  145. BANERJEE R, Raghunathan N
    Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease?
    Aliment Pharmacol Ther. 2022;55:740-741.
    PubMed    


  146. KIM ES, Kang B
    Editorial: a paradigm shift in NUDT15 assessment-towards predictive and personalised medicine in Crohn's disease? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:742-743.
    PubMed    


    February 2022
  147. BALLESTER MP, Mesonero F, Florez-Diez P, Gomez C, et al
    Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study.
    Aliment Pharmacol Ther. 2022 Feb 27. doi: 10.1111/apt.16832.
    PubMed     Abstract available


  148. SAGAMI S, Kobayashi T, Aihara K, Umeda M, et al
    Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Feb 25. doi: 10.1111/apt.16817.
    PubMed     Abstract available


  149. YE Z, Qian L, Hu W, Miao S, et al
    Clinical outcome of infantile-onset inflammatory bowel disease in 102 patients with interleukin-10 signalling deficiency.
    Aliment Pharmacol Ther. 2022 Feb 20. doi: 10.1111/apt.16837.
    PubMed     Abstract available


  150. GROSSBERG LB, Papamichael K, Cheifetz AS
    Review: emerging drug therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16785.
    PubMed     Abstract available


  151. WAN J, Wang X, Zhang Y, Chen M, et al
    Systematic review and meta-analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and low-grade dysplasia.
    Aliment Pharmacol Ther. 2022 Feb 15. doi: 10.1111/apt.16789.
    PubMed     Abstract available


  152. DEPUTY M, Sahnan K, Worley G, Patel K, et al
    The use of, and outcomes for, inflammatory bowel disease services during the Covid-19 pandemic: a nationwide observational study.
    Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16800.
    PubMed     Abstract available


  153. SCHREIBER S, Irving PM, Sharara AI, Martin-Arranz MD, et al
    Review: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions.
    Aliment Pharmacol Ther. 2022 Feb 7. doi: 10.1111/apt.16781.
    PubMed     Abstract available


  154. POLLOK RCG, Jayasooriya N
    Editorial: early and persistent biological treatment and its impact on long term surgical outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:370-371.
    PubMed    


  155. TAXONERA C
    Editorial: real-world safety of tofacitinib in ulcerative colitis.
    Aliment Pharmacol Ther. 2022;55:368-369.
    PubMed    


  156. MAHMOUD R, Schultheiss JPD, Fidder HH, Oldenburg B, et al
    Letter: loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2022;55:499-500.
    PubMed    


  157. BEN-HORIN S, Ungar B
    Letter: loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease depends on treatment duration.
    Aliment Pharmacol Ther. 2022;55:497-498.
    PubMed    


  158. GOODSALL TM, Bryant RV
    Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US.
    Aliment Pharmacol Ther. 2022;55:360-361.
    PubMed    


  159. ALLOCCA M, Danese S
    Editorial: an accurate, reliable and responsive ultrasound activity score for Crohn's disease? Sounds good to US. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:362-363.
    PubMed    


  160. ALLOCCA M, Craviotto V, Dell'Avalle C, Furfaro F, et al
    Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2022;55:446-454.
    PubMed     Abstract available


  161. SKEJO C, Vestergaard T, Julsgaard M
    Editorial: safety of ustekinumab in pregnancy-are we there yet?
    Aliment Pharmacol Ther. 2022;55:495-496.
    PubMed    


  162. CARON B, Fumery M, Netter P, Peyrin-Biroulet L, et al
    Letter: treatment with subcutaneous CT-P13 in Crohn's disease patients with intravenous infliximab failure.
    Aliment Pharmacol Ther. 2022;55:508-509.
    PubMed    


  163. PARROT L, Dong C, Carbonnel F, Meyer A, et al
    Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
    Aliment Pharmacol Ther. 2022;55:380-388.
    PubMed     Abstract available


    January 2022
  164. THOMSEN SB, Ungaro RC, Allin KH, Elmahdi R, et al
    Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
    Aliment Pharmacol Ther. 2022 Jan 25. doi: 10.1111/apt.16777.
    PubMed     Abstract available


  165. DANESE S, Levesque BG, Feagan BG, Jucov A, et al
    Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1alpha stabiliser, for treatment of ulcerative colitis.
    Aliment Pharmacol Ther. 2022 Jan 10. doi: 10.1111/apt.16753.
    PubMed     Abstract available


  166. VEISMAN I, Ben-Horin S
    Editorial: tofacitinib post-marketing safety reports among ulcerative colitis patients.
    Aliment Pharmacol Ther. 2022;55:131-132.
    PubMed    


  167. LAHARIE D, Riviere P
    Editorial: don't forget basic performance measures in the endoscopic assessment of ulcerative colitis.
    Aliment Pharmacol Ther. 2022;55:129-130.
    PubMed    


  168. CARBONNEL F, Meyer A
    Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences.
    Aliment Pharmacol Ther. 2022;55:251-252.
    PubMed    


  169. GOREN I, Yanai H
    Editorial: risk of loss of response to anti-TNFalpha agents in patients with inflammatory bowel disease-the longer the less?
    Aliment Pharmacol Ther. 2022;55:244-245.
    PubMed    


  170. HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
    Editorial: subcutaneous CT-P13 in Crohn's disease and ulcerative colitis-small change, big consequences. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:253-254.
    PubMed    


  171. VASUDEVAN A, van Langenberg DR
    Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy.
    Aliment Pharmacol Ther. 2022;55:108-109.
    PubMed    


  172. BURISCH J, Langholz E, Munkholm P
    Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy-authors' reply.
    Aliment Pharmacol Ther. 2022;55:110-111.
    PubMed    


  173. KHAN N, Patel D, Trivedi C, Pernes T, et al
    The impact of IBD medications on risk of pneumonia and pneumonia-related hospitalisation: a nationwide cohort study of 56 410 IBD patients.
    Aliment Pharmacol Ther. 2022;55:64-72.
    PubMed     Abstract available


  174. BURISCH J, Lophaven S, Langholz E, Munkholm P, et al
    The clinical course of Crohn's disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962-2017.
    Aliment Pharmacol Ther. 2022;55:73-82.
    PubMed     Abstract available


  175. REZAZADEH ARDABILI A, Mujagic Z, Jonkers DMAE, Pierik MJ, et al
    Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring.
    Aliment Pharmacol Ther. 2022;55:260-261.
    PubMed    


  176. SCHULTHEISS JPD, Mahmoud R, Fidder HH, Oldenburg B, et al
    Editorial: risk of loss of response to anti TNFalpha in patients with inflammatory bowel diseases - the longer the less? Authors' reply.
    Aliment Pharmacol Ther. 2022;55:246.
    PubMed    


  177. KHAN N, Yang YX
    Letter: screening for infectious side effects in patients with IBD-the importance and potential of real-world remote monitoring. Authors' reply.
    Aliment Pharmacol Ther. 2022;55:262.
    PubMed    


  178. MA C, MacDonald JK, Nguyen TM, Chang J, et al
    Systematic review: disease activity indices for immune checkpoint inhibitor-associated enterocolitis.
    Aliment Pharmacol Ther. 2022;55:178-190.
    PubMed     Abstract available


    December 2021
  179. WANG J, Goren I, Yang B, Lin S, et al
    The sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis: a unique therapeutic target in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Dec 21. doi: 10.1111/apt.16741.
    PubMed     Abstract available


  180. FLANAGAN E, Prentice R, Wright EK, Gibson PR, et al
    Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16739.
    PubMed     Abstract available


  181. FORSS A, Clements M, Bergman D, Roelstraete B, et al
    A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16735.
    PubMed     Abstract available


  182. HADI Y, Dulai PS, Kupec J, Mohy-Ud-Din N, et al
    Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis.
    Aliment Pharmacol Ther. 2021 Dec 14. doi: 10.1111/apt.16730.
    PubMed     Abstract available


  183. CASEY K, Lopes EW, Niccum B, Burke K, et al
    Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts.
    Aliment Pharmacol Ther. 2021 Dec 8. doi: 10.1111/apt.16731.
    PubMed     Abstract available


  184. MESERVE J, Singh S
    Editorial: risk of pneumonia in IBD-reading between the lines!
    Aliment Pharmacol Ther. 2021;54.
    PubMed    


  185. HAMDEH S, Micic D, Hanauer S
    Review article: drug-induced small bowel injury.
    Aliment Pharmacol Ther. 2021;54.
    PubMed     Abstract available


  186. SANDBORN WJ, Lawendy N, Danese S, Su C, et al
    Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
    Aliment Pharmacol Ther. 2021 Dec 1. doi: 10.1111/apt.16712.
    PubMed     Abstract available


    November 2021
  187. ZHAO M, Feng R, Ben-Horin S, Zhuang X, et al
    Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations.
    Aliment Pharmacol Ther. 2021 Nov 24. doi: 10.1111/apt.16703.
    PubMed     Abstract available


  188. RADHAKRISHNAN ST, Alexander JL, Mullish BH, Gallagher KI, et al
    Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Nov 9. doi: 10.1111/apt.16656.
    PubMed     Abstract available


  189. CHAO K, Huang Y, Zhu X, Tang J, et al
    Randomised clinical trial: dose optimising strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1124-1133.
    PubMed     Abstract available


    October 2021
  190. BURISCH J, Lophaven S, Munkholm P, Langholz E, et al
    Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962-1987 and followed until 2017 in a Danish population-based inception cohort.
    Aliment Pharmacol Ther. 2021 Oct 29. doi: 10.1111/apt.16677.
    PubMed     Abstract available


  191. BEZZIO C, Armuzzi A, Furfaro F, Ardizzone S, et al
    Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
    Aliment Pharmacol Ther. 2021 Oct 25. doi: 10.1111/apt.16663.
    PubMed     Abstract available


  192. PASVOL TJ, Bloom S, Segal AW, Rait G, et al
    Use of contraceptives and risk of inflammatory bowel disease: A nested case-control study.
    Aliment Pharmacol Ther. 2021 Oct 18. doi: 10.1111/apt.16647.
    PubMed     Abstract available


  193. RUBIN DT, Modesto I, Vermeire S, Danese S, et al
    Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Oct 9. doi: 10.1111/apt.16619.
    PubMed     Abstract available


  194. FEAGAN BG, Khanna R, Sandborn WJ, Vermeire S, et al
    Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials.
    Aliment Pharmacol Ther. 2021 Oct 6. doi: 10.1111/apt.16626.
    PubMed     Abstract available


  195. TAKENAKA K, Kawamoto A, Ohtsuka K
    Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2021;54:1087.
    PubMed    


  196. RAKOWSKY S, Cheifetz AS, Papamichael K
    Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1085-1086.
    PubMed    


  197. JOLVING LR, Anru PL, Nielsen J, Friedman S, et al
    The risk of chronic diseases and congenital malformations during childhood and adolescence after in utero exposure to thiopurines.
    Aliment Pharmacol Ther. 2021;54:1061-1069.
    PubMed     Abstract available


  198. SAINZ E, Zabana Y, Miguel I, Fernandez-Clotet A, et al
    Clinical features, therapeutic requirements and evolution of patients with Crohn's disease and upper gastrointestinal involvement (CROHNEX study).
    Aliment Pharmacol Ther. 2021;54:1041-1051.
    PubMed     Abstract available


  199. TAKENAKA K, Kawamoto A, Hibiya S, Suzuki K, et al
    Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:1052-1060.
    PubMed     Abstract available


    September 2021
  200. MULES TC, Swaminathan A, Hirschfeld E, Borichevsky G, et al
    The impact of disease activity on psychological symptoms and quality of life in patients with inflammatory bowel disease-results from the Stress, Anxiety and Depression with Disease Activity (SADD) Study.
    Aliment Pharmacol Ther. 2021 Sep 29. doi: 10.1111/apt.16616.
    PubMed     Abstract available


  201. SCHULTHEISS JPD, Mahmoud R, Louwers JM, van der Kaaij MT, et al
    Loss of response to anti-TNFalpha agents depends on treatment duration in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16605.
    PubMed     Abstract available


  202. HANZEL J, Bukkems LH, Gecse KB, D'Haens GR, et al
    Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Sep 24. doi: 10.1111/apt.16609.
    PubMed     Abstract available


  203. DOHERTY J, Fennessy S, Stack R, O' Morain N, et al
    Review Article: Vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
    Aliment Pharmacol Ther. 2021 Sep 2. doi: 10.1111/apt.16590.
    PubMed     Abstract available


  204. SAITTA D, Garg M
    Letter: missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease-still significant room for improvement.
    Aliment Pharmacol Ther. 2021;54:734-735.
    PubMed    


  205. BLESL A, Hogenauer C, Borenich A, Berghold A, et al
    Editorial: does anti-TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:720-721.
    PubMed    


  206. BLESL A, Binder L, Hogenauer C, Wenzl H, et al
    Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.
    Aliment Pharmacol Ther. 2021;54:667-677.
    PubMed     Abstract available


  207. VISURI I, Eriksson C, Olen O, Cao Y, et al
    Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply.
    Aliment Pharmacol Ther. 2021;54:848-849.
    PubMed    


  208. VEYRARD P, Nancey S, Roblin X
    Editorial: 5-ASA in IBD patients on biologics-'stop or continue'?
    Aliment Pharmacol Ther. 2021;54:843-844.
    PubMed    


  209. BERNSTEIN CN, Tennakoon A, Singh H, Targownik L, et al
    Editorial: 5-ASA in IBD patients on biologics-'stop or continue'? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:845.
    PubMed    


  210. HAYDEK JP, Scott FI
    Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence.
    Aliment Pharmacol Ther. 2021;54:846-847.
    PubMed    


  211. PIERRE N, Salee C, Vieujean S, Bequet E, et al
    Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology.
    Aliment Pharmacol Ther. 2021;54:779-791.
    PubMed     Abstract available


  212. BERNSTEIN CN, Tenakoon A, Singh H, Targownik LE, et al
    Continued 5ASA use after initiation of anti-TNF or immunomodulator confers no benefit in IBD: a population-based study.
    Aliment Pharmacol Ther. 2021;54:814-832.
    PubMed     Abstract available


    August 2021
  213. SLEUTJES JAM, Roeters van Lennep JE, Boersma E, Menchen LA, et al
    Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels.
    Aliment Pharmacol Ther. 2021 Aug 28. doi: 10.1111/apt.16580.
    PubMed     Abstract available


  214. HONAP S, Pavlidis P, Irving PM
    Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2021;54:341-342.
    PubMed    


  215. BIEMANS VBC, Straatmijer T, Hoentjen F, Pierik MJ, et al
    Letter: tofacitinib in treatment-refractory ulcerative colitis-a single centre real-world experience in Australia. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:534-535.
    PubMed    


  216. LO SW, Connell W, Kamm MA, Lust M, et al
    Letter: tofacitinib in biologic-experienced ulcerative colitis-a single-centre real-world experience in Australia.
    Aliment Pharmacol Ther. 2021;54:532-533.
    PubMed    


  217. ROBLIN X, Nancey S, Paul S
    Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:538-539.
    PubMed    


  218. FRIEDMAN AB, Gibson PR
    Editorial: assessment of inflammatory bowel disease: a picture is worth a thousand words. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:510.
    PubMed    


  219. HORJUS-TALABUR HORJE CS, van Bodegraven AA
    Editorial: assessment of inflammatory bowel disease-a picture is worth a thousand words.
    Aliment Pharmacol Ther. 2021;54:508-509.
    PubMed    


  220. TSOI AH, Murugasu A, Garg M
    Letter: assessment of histological disease activity in Crohn's disease clinical trials-a step in the right direction, but further optimisation needed.
    Aliment Pharmacol Ther. 2021;54:541-542.
    PubMed    


  221. DEMARZO MG, Bodini G, Giuliana E, Zentilin P, et al
    Letter: predictive factors for treatment discontinuation in IBD-anti-TNF trough levels and anti-drug antibodies.
    Aliment Pharmacol Ther. 2021;54:536-537.
    PubMed    


  222. MATTOO VY, Basnayake C, Connell WR, Ding N, et al
    Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2021;54:249-266.
    PubMed     Abstract available


    July 2021
  223. LAMBERT K, Pappas D, Miglioretto C, Javadpour A, et al
    Systematic review with meta-analysis: dietary intake in adults with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jul 29. doi: 10.1111/apt.16549.
    PubMed     Abstract available


  224. FUMERY M, Filippi J, Abitbol V, Biron A, et al
    Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
    Aliment Pharmacol Ther. 2021 Jul 23. doi: 10.1111/apt.16544.
    PubMed     Abstract available


  225. VISURI I, Eriksson C, Olen O, Cao Y, et al
    Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.
    Aliment Pharmacol Ther. 2021 Jul 19. doi: 10.1111/apt.16525.
    PubMed     Abstract available


  226. MCGING JJ, Radford SJ, Francis ST, Serres S, et al
    Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies.
    Aliment Pharmacol Ther. 2021 Jul 6. doi: 10.1111/apt.16465.
    PubMed     Abstract available


  227. LUBER RP, O'Neill R, Singh S, Sharma E, et al
    An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.
    Aliment Pharmacol Ther. 2021 Jul 5. doi: 10.1111/apt.16497.
    PubMed     Abstract available


  228. ROTONDO-TRIVETTE S, Wang B, Gayer C, Parsana R, et al
    Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection.
    Aliment Pharmacol Ther. 2021 Jul 4. doi: 10.1111/apt.16496.
    PubMed     Abstract available


  229. OSENI E, Sultan K
    Letter: opioid use, early biologic discontinuation for inflammatory bowel disease and a cautionary note for the age of legalised cannabis.
    Aliment Pharmacol Ther. 2021;54:92-93.
    PubMed    


  230. JORDI SBU, Misselwitz B, Begre S
    Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2021;54:82-83.
    PubMed    


  231. KNOWLES SR, Mikocka-Walus A
    Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021;54:80-81.
    PubMed    


  232. FAN D, Gearry RB
    Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?
    Aliment Pharmacol Ther. 2021;54:208-209.
    PubMed    


  233. TASSONE D, Singh S, Sheng Ding N
    Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib.
    Aliment Pharmacol Ther. 2021;54:206-207.
    PubMed    


  234. MEYER A, Semenzato L, Zureik M, Weill A, et al
    Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
    Aliment Pharmacol Ther. 2021;54:160-166.
    PubMed     Abstract available


  235. CASANOVA MJ, Chaparro M, Gisbert JP
    Editorial: withdrawal of anti-TNFalpha-are we ready for biological therapy cycling? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:86-87.
    PubMed    


  236. PUGLIESE D, Armuzzi A
    Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling?
    Aliment Pharmacol Ther. 2021;54:84-85.
    PubMed    


  237. WEISSHOF R, Chowers Y, Kurnik D
    Editorial: safety of thiopurines in pregnancy-considering the mother, foetus and newborn.
    Aliment Pharmacol Ther. 2021;54:88-89.
    PubMed    


    June 2021
  238. FARRAYE FA, Qazi T, Kotze PG, Moore GT, et al
    The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.
    Aliment Pharmacol Ther. 2021 Jun 24. doi: 10.1111/apt.16439.
    PubMed     Abstract available


  239. MEYER A, Drouin J, Weill A, Carbonnel F, et al
    Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
    Aliment Pharmacol Ther. 2021 Jun 23. doi: 10.1111/apt.16448.
    PubMed     Abstract available


  240. FRIEDMAN AB, Asthana A, Knowles SR, Robbins A, et al
    Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16452.
    PubMed     Abstract available


  241. BERNSTEIN CN, Nugent Z, Shaffer S, Singh H, et al
    Comorbidity before and after a diagnosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 22. doi: 10.1111/apt.16444.
    PubMed     Abstract available


  242. UZZAN M, Bresteau C, Laharie D, Stefanescu C, et al
    Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16463.
    PubMed     Abstract available


  243. KO Y, Paramsothy S, Yau Y, Leong RW, et al
    Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Aliment Pharmacol Ther. 2021 Jun 20. doi: 10.1111/apt.16436.
    PubMed     Abstract available


  244. VAN LINSCHOTEN RCA, Visser E, Niehot CD, van der Woude CJ, et al
    Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16445.
    PubMed     Abstract available


  245. FAIRBRASS KM, Gracie DJ, Ford AC
    Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16454.
    PubMed     Abstract available


  246. LAMB CA, Sebastian S, Kent AJ, Segal JP, et al
    Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
    Aliment Pharmacol Ther. 2021;53:1236-1240.
    PubMed    


  247. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
    Editorial: trends in paediatric inflammatory bowel disease attributable direct costs-authors' reply.
    Aliment Pharmacol Ther. 2021;53:1234-1235.
    PubMed    


  248. VERNON-ROBERTS A, Day AS
    Editorial: trends in paediatric inflammatory bowel disease attributable direct costs.
    Aliment Pharmacol Ther. 2021;53:1232-1233.
    PubMed    


  249. TANNOURY J, Amiot A
    Editorial: determining disability in inflammatory bowel disease-"See(k) and you shall find". Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1323.
    PubMed    


  250. TURBAYNE AKB, Ward MG
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind.
    Aliment Pharmacol Ther. 2021;53:1317-1318.
    PubMed    


  251. ROBLIN X, Nancey S, Paul S
    Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1319-1320.
    PubMed    


  252. LIMDI JK
    Editorial: determining disability in IBD - 'See(k) and you shall find'.
    Aliment Pharmacol Ther. 2021;53:1321-1322.
    PubMed    


  253. MANLAY L, Boschetti G, Pereira B, Flourie B, et al
    Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Aliment Pharmacol Ther. 2021;53:1289-1299.
    PubMed     Abstract available


    May 2021
  254. JORDI SBU, Botte F, Lang BM, Greuter T, et al
    Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 May 11. doi: 10.1111/apt.16365.
    PubMed     Abstract available


  255. CASANOVA MJ, Chaparro M, Nantes O, Benitez JM, et al
    Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.
    Aliment Pharmacol Ther. 2021 May 7. doi: 10.1111/apt.16361.
    PubMed     Abstract available


  256. SRINIVASAN A, Haifer C, Thin L
    Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD.
    Aliment Pharmacol Ther. 2021;53:1038-1039.
    PubMed    


  257. WILSON A, Kim RB
    Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-alpha antagonist immunogenicity - does location matter?
    Aliment Pharmacol Ther. 2021;53:1055-1056.
    PubMed    


  258. DEMARZO MG, Bodini G, Vanello M, Martini M, et al
    Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.
    Aliment Pharmacol Ther. 2021;53:1044-1045.
    PubMed    


  259. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1046-1047.
    PubMed    


  260. MESONERO F, Castro-Poceiro J, Benitez JM, Camps B, et al
    Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-alpha: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2021;53:1021-1029.
    PubMed     Abstract available


  261. SEDANO R, Ma C, Jairath V
    Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:1149-1150.
    PubMed    


  262. LAUBE R, Selinger CP
    Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction.
    Aliment Pharmacol Ther. 2021;53:1147-1148.
    PubMed    


  263. TANNOURY J, Nachury M, Martins C, Serrero M, et al
    Determinants of IBD-related disability: a cross-sectional survey from the GETAID.
    Aliment Pharmacol Ther. 2021;53:1098-1107.
    PubMed     Abstract available


  264. TJANDRA D, Garg M, Behrenbruch C, McCormick J, et al
    Review article: investigation and management of internal fistulae in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:1064-1079.
    PubMed     Abstract available


    April 2021
  265. DHALIWAL J, McKay HE, Deslandres C, Debruyn J, et al
    One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Aliment Pharmacol Ther. 2021 Apr 28. doi: 10.1111/apt.16388.
    PubMed     Abstract available


  266. TOURNIER Q, Paul S, Williet N, Berger AE, et al
    Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Apr 19. doi: 10.1111/apt.16333.
    PubMed     Abstract available


  267. EL-MATARY W, Nugent Z, Witt J, Bernstein CN, et al
    Trends in paediatric inflammatory bowel disease-attributable direct costs: a population-based analysis.
    Aliment Pharmacol Ther. 2021 Apr 9. doi: 10.1111/apt.16358.
    PubMed     Abstract available


  268. VAN DER HAVE M, Maljaars J
    Editorial: opioids in inflammatory bowel disease-primum non nocere.
    Aliment Pharmacol Ther. 2021;53:844-845.
    PubMed    


  269. RHUDY C, Perry CL, Barrett TA
    Editorial: opioids in inflammatory bowel disease-primum non nocere. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:846.
    PubMed    


  270. JANGI S, Yoon H, Dulai P, Valasek M, et al
    Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply.
    Aliment Pharmacol Ther. 2021;53:957-958.
    PubMed    


  271. MAEDA Y, Kudo SE, Takishima K, Misawa M, et al
    Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis.
    Aliment Pharmacol Ther. 2021;53:955-956.
    PubMed    


  272. PRENTICE RE, Hollingsworth L, Middleton C, Wilson J, et al
    Letter: colorectal cancer surveillance in inflammatory bowel disease-a call for systematic reform.
    Aliment Pharmacol Ther. 2021;53:953-954.
    PubMed    


  273. LUBELL JM
    Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes.
    Aliment Pharmacol Ther. 2021;53:851-852.
    PubMed    


  274. BAGER P, Hvas C, Rud C, Dahlerup J, et al
    Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:853-854.
    PubMed    


  275. LIM G, Kassam Z, Seow CH
    Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity?
    Aliment Pharmacol Ther. 2021;53:855-856.
    PubMed    


  276. TURSI A, Mocci G, Picchio M, Elisei W, et al
    Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:859-860.
    PubMed    


  277. LAHARIE D, Riviere P
    Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:857-858.
    PubMed    


  278. ALMRADI A, Ma C, D'Haens GR, Sandborn WJ, et al
    An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials.
    Aliment Pharmacol Ther. 2021;53:784-793.
    PubMed     Abstract available


  279. ABUSHAMMA S, Deepak P
    Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials-is it ready for prime time yet?
    Aliment Pharmacol Ther. 2021;53:946-947.
    PubMed    


  280. JAIRATH V, Almradi A, Pai RK, Ma C, et al
    Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials-a missing link. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:952.
    PubMed    


  281. TANDON P, Narula N
    Editorial: methotrexate in patients with Crohn's disease refractory to anti-TNF therapy-moving backwards yet forward?
    Aliment Pharmacol Ther. 2021;53:950-951.
    PubMed    


  282. GOODSALL TM, Jairath V, Bryant RV, Ma C, et al
    Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials - is it ready for prime time yet? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:948-949.
    PubMed    


  283. GOODSALL TM, Jairath V, Feagan BG, Parker CE, et al
    Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:873-886.
    PubMed     Abstract available


    March 2021
  284. WORLEY G, Faiz O
    Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:661-662.
    PubMed    


  285. BODGER K
    Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages?
    Aliment Pharmacol Ther. 2021;53:660.
    PubMed    


  286. LAHARIE D
    Editorial: is enteral nutrition back in acute severe ulcerative colitis?
    Aliment Pharmacol Ther. 2021;53:745-746.
    PubMed    


  287. AL-ANI AH, Prentice RE, Rentsch C, Christensen B, et al
    Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.
    Aliment Pharmacol Ther. 2021;53:766-767.
    PubMed    


  288. SAHU P, Kedia S, Kumar Vuyyuru S, Travis S, et al
    Editorial: is enteral nutrition back in acute severe ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:747-748.
    PubMed    


  289. O'MORAIN N, Coe C, Mallon P, Twomey P, et al
    Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active?
    Aliment Pharmacol Ther. 2021;53:674-675.
    PubMed    


  290. PRIVITERA G, Pugliese D, Scaldaferri F, Armuzzi A, et al
    Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.
    Aliment Pharmacol Ther. 2021;53:764-765.
    PubMed    


  291. TRYSTRAM N, Abitbol V, Tannoury J, Lecomte M, et al
    Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16312.
    PubMed     Abstract available


  292. KANESHIRO M, Takenaka K, Suzuki K, Fujii T, et al
    Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission.
    Aliment Pharmacol Ther. 2021 Mar 1. doi: 10.1111/apt.16310.
    PubMed     Abstract available


  293. MANTZARIS GJ, Bamias G
    Editorial: an expert consensus to standardise the assessment of histologic disease activity in Crohn's disease clinical trials-a missing link.
    Aliment Pharmacol Ther. 2021;53:749-750.
    PubMed    


  294. ROBLIN X, Paul S, Nancey S
    Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game.
    Aliment Pharmacol Ther. 2021;53:640-641.
    PubMed    


  295. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.
    Aliment Pharmacol Ther. 2021;53:642-643.
    PubMed    


  296. MCCURDY J, Boet S, Rosenfeld G
    Editorial: is hyperbaric oxygen a therapeutic opportunity for refractory perianal Crohn's disease?
    Aliment Pharmacol Ther. 2021;53:667-668.
    PubMed    


  297. LAFEUILLE P, Hordonneau C, Vignette J, Blayac L, et al
    Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:577-586.
    PubMed     Abstract available


  298. LANSDORP CA, Gecse KB, Buskens CJ, Lowenberg M, et al
    Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:587-597.
    PubMed     Abstract available


    February 2021
  299. FLANAGAN E, Wright EK, Hardikar W, Sparrow MP, et al
    Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates.
    Aliment Pharmacol Ther. 2021 Feb 19. doi: 10.1111/apt.16294.
    PubMed     Abstract available


  300. JAHRAUS CD
    Editorial: "Please Sir, I want some more" data to guide delivery of abdominopelvic radiotherapy in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021;53:454-455.
    PubMed    


  301. AXELRAD JE
    Editorial: immune-mediated diseases-are we closer to disease-defining molecular signatures?
    Aliment Pharmacol Ther. 2021;53:563-564.
    PubMed    


  302. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
    Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:445-446.
    PubMed    


  303. WILS P, Pariente B
    Editorial: keep calm and carry on-managing non-TNF antagonist biologics in pregnancy-authors' reply.
    Aliment Pharmacol Ther. 2021;53:452-453.
    PubMed    


  304. SEOW CH, Ma C
    Keep calm and carry on-managing non-TNF antagonist biologics in pregnancy.
    Aliment Pharmacol Ther. 2021;53:450-451.
    PubMed    


  305. TOWNSEND T, Subramanian S
    Editorial: vedolizumab in inflammatory bowel diseases-less is more?
    Aliment Pharmacol Ther. 2021;53:443-444.
    PubMed    


  306. MESERVE J, Facciorusso A, Holmer AK, Annese V, et al
    Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2021;53:374-382.
    PubMed     Abstract available


    January 2021
  307. RHUDY C, Perry CL, Singleton M, Talbert J, et al
    Chronic opioid use is associated with early biologic discontinuation in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2021 Jan 26. doi: 10.1111/apt.16269.
    PubMed     Abstract available


  308. SAHU P, Kedia S, Vuyyuru SK, Bajaj A, et al
    Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2021 Jan 13. doi: 10.1111/apt.16249.
    PubMed     Abstract available


  309. CHEE D, Kennedy NA, Goodhand JR, Ahmad T, et al
    Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:337-338.
    PubMed    


  310. MAHMOUD R, Itzkowitz SH
    Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease-getting to the root.
    Aliment Pharmacol Ther. 2021;53:335-336.
    PubMed    


  311. LORD A, Radford-Smith G
    Letter: hidden costs in healthcare use for incident and prevalent Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2021;53:368-369.
    PubMed    


  312. RIMOLA J, Panes J, Ordas I
    Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease-authors' reply.
    Aliment Pharmacol Ther. 2021;53:207-208.
    PubMed    


  313. DEBNATH P, Rathi P
    Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:205-206.
    PubMed    


  314. MURRAY CD
    Editorial: fatigue-difficult to assess and difficult to treat.
    Aliment Pharmacol Ther. 2021;53:339.
    PubMed    


  315. LEBLANC JF, Hart AL
    Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD.
    Aliment Pharmacol Ther. 2021;53:342-343.
    PubMed    


  316. TOWNSEND T, Subramanian S
    Letter: propensity score-handle with care. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:362-363.
    PubMed    


  317. MACALUSO FS, Orlando A
    Letter: propensity score-handle with care.
    Aliment Pharmacol Ther. 2021;53:360-361.
    PubMed    


  318. CARBERY I, Selinger CP
    Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD?
    Aliment Pharmacol Ther. 2021;53:346-347.
    PubMed    


  319. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:344-345.
    PubMed    


  320. SCHREINER P, von Kanel R, Misselwitz B
    Editorial: fatigue-difficult to assess and difficult to treat. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:340-341.
    PubMed    


  321. BERTANI L, Pugliese D, Trico D, Costa F, et al
    Editorial: can serum triiodothyronine-to-thyroxine (T3/T4) ratio predict safety and efficacy of biologic treatment in IBD? Authors' reply.
    Aliment Pharmacol Ther. 2021;53:348-349.
    PubMed    


  322. NICE R, Chanchlani N, Green H, Bewshea C, et al
    Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays.
    Aliment Pharmacol Ther. 2021;53:128-137.
    PubMed     Abstract available


  323. DANESE S, Subramaniam K, Van Zyl J, Adsul S, et al
    Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme.
    Aliment Pharmacol Ther. 2021;53:265-272.
    PubMed     Abstract available


  324. BERTANI L, Trico D, Pugliese D, Privitera G, et al
    Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients.
    Aliment Pharmacol Ther. 2021;53:273-280.
    PubMed     Abstract available


  325. FRAZZONI L, La Marca M, Radaelli F, Spada C, et al
    Systematic review with meta-analysis: the appropriateness of colonoscopy increases the probability of relevant findings and cancer while reducing unnecessary exams.
    Aliment Pharmacol Ther. 2021;53:22-32.
    PubMed     Abstract available


  326. PAI RK, Pai RK, Brown I, Choi WT, et al
    The significance of histological activity measurements in immune checkpoint inhibitor colitis.
    Aliment Pharmacol Ther. 2021;53:150-159.
    PubMed     Abstract available


  327. UNGARO RC, Hu L, Ji J, Nayar S, et al
    Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2021;53:281-290.
    PubMed     Abstract available


  328. KING D, Coupland B, Dosanjh A, Cole A, et al
    The risk of later surgery at the anastomotic site following right hemicolectomy for Crohn's disease in a national cohort of 12 230 patients.
    Aliment Pharmacol Ther. 2021;53:114-127.
    PubMed     Abstract available


    December 2020
  329. RUNDQUIST S, Sachs MC, Eriksson C, Olen O, et al
    Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.
    Aliment Pharmacol Ther. 2020 Dec 19. doi: 10.1111/apt.16193.
    PubMed     Abstract available


  330. YE L, Chapman TP, Wen Z, Lin L, et al
    Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region.
    Aliment Pharmacol Ther. 2020 Dec 12. doi: 10.1111/apt.16130.
    PubMed     Abstract available


  331. PIOVANI D, Pansieri C, Peyrin-Biroulet L, Danese S, et al
    Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study.
    Aliment Pharmacol Ther. 2020 Dec 9. doi: 10.1111/apt.16222.
    PubMed     Abstract available


  332. WILS P, Seksik P, Stefanescu C, Nancey S, et al
    Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study.
    Aliment Pharmacol Ther. 2020 Dec 7. doi: 10.1111/apt.16192.
    PubMed     Abstract available


  333. LO CH, Khalili H, Lochhead P, Song M, et al
    Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study.
    Aliment Pharmacol Ther. 2020 Dec 5. doi: 10.1111/apt.16210.
    PubMed     Abstract available


  334. WORLEY G, Almoudaris A, Bassett P, Segal J, et al
    Colectomy rates for ulcerative colitis in England 2003-2016.
    Aliment Pharmacol Ther. 2020 Dec 2. doi: 10.1111/apt.16202.
    PubMed     Abstract available


  335. REUKEN PA, Wust M, Loffler B, Bauer M, et al
    Letter: SARS-CoV-2-induced gastrointestinal inflammation.
    Aliment Pharmacol Ther. 2020;52.
    PubMed    


    November 2020
  336. DOHOS D, Hanak L, Szakacs Z, Kiss S, et al
    Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 28. doi: 10.1111/apt.16182.
    PubMed     Abstract available


  337. BROUSSARD D, Riviere P, Bonnet J, Fotsing G, et al
    Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID.
    Aliment Pharmacol Ther. 2020 Nov 26. doi: 10.1111/apt.16176.
    PubMed     Abstract available


  338. BAGER P, Hvas CL, Rud CL, Dahlerup JF, et al
    Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16166.
    PubMed     Abstract available


  339. HIBIYA S, Matsuyama Y, Fujii T, Maeyashiki C, et al
    5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16120.
    PubMed     Abstract available


  340. SCHREINER P, Rossel JB, Biedermann L, Valko PO, et al
    Fatigue in inflammatory bowel disease and its impact on daily activities.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16145.
    PubMed     Abstract available


  341. GORDON C, Chee D, Hamilton B, Heerasing NM, et al
    Root-cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020 Nov 7. doi: 10.1111/apt.16155.
    PubMed     Abstract available


  342. MEYER A, Drouin J, Weill A, Carbonnel F, et al
    Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018.
    Aliment Pharmacol Ther. 2020;52:1480-1490.
    PubMed     Abstract available


  343. NICOLAIDES S, Vasudevan A, van Langenberg D
    Letter: rationalising aminosalicylates in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2020;52:1619-1620.
    PubMed    


  344. MA C, Singh S, Heatherington J, Panaccione R, et al
    Editorial: is age just a number when it comes to treatment of inflammatory bowel disease?
    Aliment Pharmacol Ther. 2020;52:1615-1616.
    PubMed    


  345. ASSCHER VER, Biemans VBC, Hoentjen F, Maljaars PWJ, et al
    Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1617-1618.
    PubMed    


  346. CHAPMAN TP, Frias Gomes C, Louis E, Colombel JF, et al
    Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1621.
    PubMed    


  347. NARULA N, Aruljothy A, Alshahrani AA, Fadida M, et al
    Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission.
    Aliment Pharmacol Ther. 2020 Nov 1. doi: 10.1111/apt.16147.
    PubMed     Abstract available


  348. VASUDEVAN A, Con D, Nicolaides S, van Langenberg DR, et al
    Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1529-1530.
    PubMed    


  349. ZULFIQAR M, Deepak P
    Editorial: crystal gazing with magnetic resonance enterography to predict the response to TNF-alpha inhibitors in Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1531-1532.
    PubMed    


  350. FRASER AG
    Methotrexate or azathioprine-do differing rates of discontinuation settle the debate?
    Aliment Pharmacol Ther. 2020;52:1527-1528.
    PubMed    


  351. FLANAGAN E, Gibson PR, Wright EK, Moore GT, et al
    Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure.
    Aliment Pharmacol Ther. 2020;52:1551-1562.
    PubMed     Abstract available


  352. TAYLOR H, Serrano-Contreras JI, McDonald JAK, Epstein J, et al
    Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1491-1502.
    PubMed     Abstract available


  353. RIMOLA J, Fernandez-Clotet A, Capozzi N, Rojas-Farreras S, et al
    Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1563-1573.
    PubMed     Abstract available


    October 2020
  354. BANERJEE R, Ravikanth VV, Pal P, Bale G, et al
    NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India.
    Aliment Pharmacol Ther. 2020 Oct 27. doi: 10.1111/apt.16137.
    PubMed     Abstract available


  355. PANACCIONE R, Danese S, Sandborn WJ, O'Brien CD, et al
    Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.
    Aliment Pharmacol Ther. 2020 Oct 21. doi: 10.1111/apt.16119.
    PubMed     Abstract available


  356. AMIOT A, Salameh R
    Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1252.
    PubMed    


  357. FABIAN A, Bor R, Farkas K, Szepes Z, et al
    Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy.
    Aliment Pharmacol Ther. 2020;52:1251.
    PubMed    


  358. PRENTICE RE, Tjandra D, Garg M, Lubel JS, et al
    Letter: ACE2, IBD and COVID-19-why IBD patients may be at reduced risk of COVID-19.
    Aliment Pharmacol Ther. 2020;52:1422-1423.
    PubMed    


  359. BRITTON E, Richardson P, Mian I, Conley T, et al
    Letter: Covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when?
    Aliment Pharmacol Ther. 2020;52:1414-1415.
    PubMed    


  360. BIEMANS VBC, Hoentjen F, Pierik MJ
    Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1255-1256.
    PubMed    


  361. LIU K, Cai F, Huang J
    Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth?
    Aliment Pharmacol Ther. 2020;52:1253-1254.
    PubMed    


  362. LAHARIE D, Riviere P
    Editorial: biologics in the therapy of Crohn's disease-the fog clears.
    Aliment Pharmacol Ther. 2020;52:1214-1215.
    PubMed    


  363. MERTZ NORGARD B, Friedman S
    Editorial: thiopurine/anti-TNF use during pregnancy-more encouraging safety data. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:1411.
    PubMed    


  364. BETTENWORTH D, Bokemeyer A, Kou L, Lopez R, et al
    Systematic review with meta-analysis: efficacy of balloon-assisted enteroscopy for dilation of small bowel Crohn's disease strictures.
    Aliment Pharmacol Ther. 2020;52:1104-1116.
    PubMed     Abstract available


  365. TOWNSEND T, Razanskaite V, Dodd S, Storey D, et al
    Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:1341-1352.
    PubMed     Abstract available


    September 2020
  366. BATTAT R, Vande Casteele N, Pai RK, Wang Z, et al
    Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.
    Aliment Pharmacol Ther. 2020 Sep 27. doi: 10.1111/apt.16083.
    PubMed     Abstract available


  367. JANGI S, Yoon H, Dulai PS, Valasek M, et al
    Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing.
    Aliment Pharmacol Ther. 2020;52:1008-1016.
    PubMed     Abstract available


  368. CHEE D, Goodhand JR, Ahmad T
    Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll-out?
    Aliment Pharmacol Ther. 2020;52:1076-1077.
    PubMed    


  369. APPLETON L, Day AS
    Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
    Aliment Pharmacol Ther. 2020;52:1080-1081.
    PubMed    


  370. ROBLIN X, Le Roy B, Paul S
    Editorial: therapeutic drug monitoring for golimumab - ready for prime time?
    Aliment Pharmacol Ther. 2020;52:1078-1079.
    PubMed    


  371. BERTANI L, Fornai M, Antonioli L, Blandizzi C, et al
    Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab-authors' reply.
    Aliment Pharmacol Ther. 2020;52:1082.
    PubMed    


  372. KOPYLOV U
    Letter: optimising response to ustekinumab therapy for patients with Crohn's disease-author's reply.
    Aliment Pharmacol Ther. 2020;52:907.
    PubMed    


  373. DESAI D, Abraham P
    Letter: monitoring interval for thiopurine therapy - a comment.
    Aliment Pharmacol Ther. 2020;52:910.
    PubMed    


  374. HUDSON J, Herfarth HH, Barnes EL
    Letter: optimising response to ustekinumab therapy for patients with Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:906.
    PubMed    


  375. JONES K, Baker K, Speight RA, Thompson NP, et al
    Randomised clinical trial: combined impact and resistance training in adults with stable Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:964-975.
    PubMed     Abstract available


  376. BROMS G, Kieler H, Ekbom A, Gissler M, et al
    Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy.
    Aliment Pharmacol Ther. 2020;52:843-854.
    PubMed     Abstract available


  377. IBORRA M, Beltran B, Fernandez-Clotet A, Iglesias-Flores E, et al
    Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2020;52:1017-1030.
    PubMed     Abstract available


    August 2020
  378. KHAN MU, Mushtaq K, Al-Ejji KMAA, Yakoob RA, et al
    Letter: IBD nurse-a pivotal role in the time of the pandemic.
    Aliment Pharmacol Ther. 2020;52:745.
    PubMed    


  379. BERTANI L, Antonioli L, Blandizzi C
    Letter: ustekinumab's effectiveness outcomes compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers?
    Aliment Pharmacol Ther. 2020;52:751-752.
    PubMed    


  380. AL-ANI AH, Rentsch CA, Azim S, Bidgood E, et al
    Letter: IBD nurse-pivotal role in the time of the pandemic. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:746-747.
    PubMed    


  381. BIEMANS VBC, Hoentjen F, Pierik MJ
    Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease-what about mucosal healing and biomarkers? Authors' reply.
    Aliment Pharmacol Ther. 2020;52:753-754.
    PubMed    


  382. MARSH A, Radford-Smith G
    Editorial: obesity management and IBD-weight loss reduces IBD risk.
    Aliment Pharmacol Ther. 2020;52:731-732.
    PubMed    


  383. KANG B, Kim TJ, Choi J, Baek SY, et al
    Adjustment of azathioprine dose should be based on a lower 6-TGN target level to avoid leucopenia in NUDT15 intermediate metabolisers.
    Aliment Pharmacol Ther. 2020;52:459-470.
    PubMed     Abstract available


  384. WALKER GJ, Lin S, Chanchlani N, Thomas A, et al
    Quality improvement project identifies factors associated with delay in IBD diagnosis.
    Aliment Pharmacol Ther. 2020;52:471-480.
    PubMed     Abstract available


  385. BOHM M, Xu R, Zhang Y, Varma S, et al
    Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
    Aliment Pharmacol Ther. 2020;52:669-681.
    PubMed     Abstract available


  386. SEGAL JP, Smith PJ
    Editorial: quality improvement project to identify factors associated with a delay in IBD diagnosis.
    Aliment Pharmacol Ther. 2020;52:733-734.
    PubMed    


    July 2020
  387. BIEMANS VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, et al
    Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Aliment Pharmacol Ther. 2020;52:123-134.
    PubMed     Abstract available


  388. KABIR M, Fofaria R, Arebi N, Bassett P, et al
    Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present).
    Aliment Pharmacol Ther. 2020;52:5-19.
    PubMed     Abstract available


  389. KOPYLOV U, Hanzel J, Liefferinckx C, De Marco D, et al
    Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
    Aliment Pharmacol Ther. 2020;52:135-142.
    PubMed     Abstract available


  390. KOCHAR B, Cai W, Cagan A, Ananthakrishnan AN, et al
    Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:311-318.
    PubMed     Abstract available


  391. THOMANN AK, Mak JWY, Zhang JW, Wuestenberg T, et al
    Review article: bugs, inflammation and mood-a microbiota-based approach to psychiatric symptoms in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2020;52:247-266.
    PubMed     Abstract available


  392. DUMONT LM, Landman C, Sokol H, Beaugerie L, et al
    Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study.
    Aliment Pharmacol Ther. 2020;52:303-310.
    PubMed     Abstract available


  393. BERTANI L, Fornai M, Fornili M, Antonioli L, et al
    Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
    Aliment Pharmacol Ther. 2020;52:284-291.
    PubMed     Abstract available


    June 2020
  394. YANG E, Panaccione N, Whitmire N, Dulai PS, et al
    Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1031-1038.
    PubMed     Abstract available


  395. LU C, Baraty B, Lee Robertson H, Filyk A, et al
    Systematic review: medical therapy for fibrostenosing Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1233-1246.
    PubMed     Abstract available


  396. SRINIVASAN A, van Langenberg DR, Little RD, Sparrow MP, et al
    A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:1342-1352.
    PubMed     Abstract available


  397. PAPOUTSOPOULOU S, Satsangi J, Campbell BJ, Probert CS, et al
    Review article: impact of cigarette smoking on intestinal inflammation-direct and indirect mechanisms.
    Aliment Pharmacol Ther. 2020;51:1268-1285.
    PubMed     Abstract available


  398. CZAJA AJ
    Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
    Aliment Pharmacol Ther. 2020;51:1286-1304.
    PubMed     Abstract available


    May 2020
  399. UNGARO RC, Aggarwal S, Topaloglu O, Lee WJ, et al
    Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease.
    Aliment Pharmacol Ther. 2020;51:831-842.
    PubMed     Abstract available


  400. CHEUNG KS, Chen L, Chan EW, Seto WK, et al
    Nonsteroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer.
    Aliment Pharmacol Ther. 2020;51:899-908.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: